Suppr超能文献

老年糖尿病患者中磺脲类药物的使用。

Use of sulfonylurea agents in older diabetic patients.

作者信息

Peters A L, Davidson M B

机构信息

Cedars-Sinai Medical Center, Los Angeles, California.

出版信息

Clin Geriatr Med. 1990 Nov;6(4):903-21.

PMID:2224754
Abstract

The elderly patient with type II diabetes should be treated in much the same fashion as a younger person with the same disease, although emphasis needs to be placed on minimizing side effects, drug interactions, and hypoglycemia. Chlorpropamide should not be used in these patients, unless there is no other choice. The remaining agents--tolbutamide, acetohexamide, tolazamide, glyburide, and glipizide--should be started at low doses and gradually increased until optimal diabetic control is reached. The initial treatment goal is a FPG level of less than 180 mg/dl and a final goal is a 1- to 2-hour PPG concentration between 140 and 180 mg/dl. The glycosylated hemoglobin value should be no greater than 1.5% above the upper limit of normal, and should be lower, if possible. It must be kept in mind, however, that the closer diabetic patients are to achieving euglycemia, the more likely is hypoglycemia. Treatment goals therefore may have to be relaxed in someone at increased risk of hypoglycemia (e.g., patients with irregular eating habits or renal insufficiency) or when hypoglycemia may pose a greater hazard (e.g., patients with coronary artery or cerebral vascular disease). Patients on sulfonylurea agents should have blood glucose values measured once a month and glycosylated hemoglobin levels determined once every 3 months to alert the clinician to the possible need to adjust therapy. In this way, potential hypoglycemia can be avoided if blood glucose levels are drifting too low and chronic hyperglycemia can be identified and treated within a short period of time. When a patient's status changes--e.g., he is placed on new medication, becomes depressed and anorexic, or develops another medical problem--care must be taken to re-evaluate his diabetes management. Drugs such as sulfonamide antibiotics can potentiate the action of the sulfonylureas and cause hypoglycemia, renal insufficiency may necessitate changing the type of sulfonylurea agent or decreasing the dose, and malnutrition may obviate any need for therapy with an oral hypoglycemic agent. If these guidelines are kept in mind, the older diabetic patient can be managed on a sulfonylurea agent in conjunction with the appropriate diet. Should these measures prove to be ineffective, then insulin therapy should be instituted. Controlling chronic hyperglycemia will help improve the quality of life for patients with diabetes and decrease the probability of developing some of the devastating complications associated with this disease.

摘要

老年II型糖尿病患者的治疗方式应与患有相同疾病的年轻人大致相同,不过需要着重尽量减少副作用、药物相互作用和低血糖情况。除非别无选择,否则不应在这些患者中使用氯磺丙脲。其余药物——甲苯磺丁脲、醋磺己脲、妥拉磺脲、格列本脲和格列吡嗪——应以低剂量开始使用,并逐渐增加剂量,直至达到最佳糖尿病控制效果。初始治疗目标是空腹血糖(FPG)水平低于180mg/dl,最终目标是餐后1至2小时血糖(PPG)浓度在140至180mg/dl之间。糖化血红蛋白值应不高于正常上限1.5%,如有可能应更低。然而,必须记住,糖尿病患者越接近实现血糖正常,发生低血糖的可能性就越大。因此,对于低血糖风险增加的患者(如饮食习惯不规律或肾功能不全的患者),或者低血糖可能带来更大危害的患者(如患有冠状动脉或脑血管疾病的患者),治疗目标可能不得不放宽。服用磺脲类药物的患者应每月测量一次血糖值,每3个月测定一次糖化血红蛋白水平,以便提醒临床医生可能需要调整治疗方案。通过这种方式,如果血糖水平过低,可以避免潜在的低血糖情况,并且可以在短时间内识别并治疗慢性高血糖。当患者的状况发生变化时——例如,开始服用新药、变得抑郁和厌食或出现其他医疗问题——必须重新评估其糖尿病管理情况。诸如磺胺类抗生素等药物可增强磺脲类药物的作用并导致低血糖,肾功能不全可能需要改变磺脲类药物的类型或降低剂量,营养不良可能无需使用口服降糖药进行治疗。如果牢记这些指导原则,老年糖尿病患者可以在服用磺脲类药物的同时配合适当饮食进行管理。如果这些措施证明无效,则应开始胰岛素治疗。控制慢性高血糖将有助于改善糖尿病患者的生活质量,并降低发生与该疾病相关的一些严重并发症的可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验